JPWO2022216759A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022216759A5 JPWO2022216759A5 JP2023561290A JP2023561290A JPWO2022216759A5 JP WO2022216759 A5 JPWO2022216759 A5 JP WO2022216759A5 JP 2023561290 A JP2023561290 A JP 2023561290A JP 2023561290 A JP2023561290 A JP 2023561290A JP WO2022216759 A5 JPWO2022216759 A5 JP WO2022216759A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antisense oligonucleotide
- unc13a
- bases
- exon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171522P | 2021-04-06 | 2021-04-06 | |
| US63/171,522 | 2021-04-06 | ||
| US202263312808P | 2022-02-22 | 2022-02-22 | |
| US63/312,808 | 2022-02-22 | ||
| PCT/US2022/023559 WO2022216759A1 (en) | 2021-04-06 | 2022-04-05 | Compositions and methods for treating tdp-43 proteinopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513237A JP2024513237A (ja) | 2024-03-22 |
| JP2024513237A5 JP2024513237A5 (https=) | 2025-04-15 |
| JPWO2022216759A5 true JPWO2022216759A5 (https=) | 2025-04-15 |
Family
ID=81384958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561290A Pending JP2024513237A (ja) | 2021-04-06 | 2022-04-05 | Ｔｄｐ－４３プロテイノパチーを処置するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250011773A1 (https=) |
| EP (1) | EP4320236A1 (https=) |
| JP (1) | JP2024513237A (https=) |
| KR (1) | KR20240004467A (https=) |
| AU (1) | AU2022255175A1 (https=) |
| CA (1) | CA3213590A1 (https=) |
| IL (1) | IL307305A (https=) |
| MX (1) | MX2023011794A (https=) |
| WO (1) | WO2022216759A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2603454A (en) * | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| CA3227115A1 (en) * | 2021-07-21 | 2023-01-26 | Wen-Hsuan Chang | Unc13a antisense oligonucleotides |
| CN119790152A (zh) * | 2021-12-03 | 2025-04-08 | 奎里斯公司 | 使用unc13a基因转录本的调节剂治疗神经系统疾病 |
| GB202117758D0 (en) * | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| CN118974254A (zh) * | 2021-12-21 | 2024-11-15 | 豪夫迈·罗氏有限公司 | 靶向unc13a的反义寡核苷酸 |
| AU2023356317A1 (en) * | 2022-10-05 | 2025-05-15 | Trace Neuroscience, Inc. | Unc13a antisense oligonucleotides and uses thereof |
| WO2024155986A2 (en) * | 2023-01-20 | 2024-07-25 | AcuraStem Incorporated | Unc13a antisense oligonucleotides |
| WO2024178223A1 (en) * | 2023-02-24 | 2024-08-29 | Northwestern University | Antisense oligonucleotides for preventing unc13a misplicing |
| AU2024283557A1 (en) * | 2023-06-02 | 2026-01-08 | Quralis Corporation | Modified unc13a oligonucleotides |
| GB202309922D0 (en) * | 2023-06-29 | 2023-08-16 | Univ Edinburgh | Antisense treatment |
| WO2025007194A1 (en) * | 2023-07-05 | 2025-01-09 | Macquarie University | Modulation of gene expression |
| GB202315883D0 (en) * | 2023-10-17 | 2023-11-29 | Univ Oxford Innovation Ltd | Method |
| WO2025186619A1 (en) * | 2024-03-05 | 2025-09-12 | Takeda Pharmaceutical Company Limited | Compositions and methods for splicing modulation of unc13a |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016528873A (ja) * | 2012-05-16 | 2016-09-23 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
| ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| EP4166667A3 (en) | 2013-10-11 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| EP4410805A3 (en) | 2014-03-18 | 2024-11-27 | University of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| BR112018012894A2 (en) | 2015-12-23 | 2018-12-04 | Crispr Therapeutics Ag | Materials and Methods for Treatment of Amyotrophic Lateral Sclerosis and / or Frontotemporal Lobular Degeneration |
| TW201920672A (zh) | 2017-08-08 | 2019-06-01 | 新加坡商波濤生命科學有限公司 | 寡核苷酸組合物及其使用方法 |
| CA3079727A1 (en) | 2017-10-24 | 2019-05-02 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of rare diseases |
| JP7795914B2 (ja) * | 2019-06-03 | 2026-01-08 | クラリス コーポレーション | 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法 |
| WO2022018187A1 (en) * | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting rna binding protein sites |
| GB2603454A (en) * | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
-
2022
- 2022-04-05 AU AU2022255175A patent/AU2022255175A1/en active Pending
- 2022-04-05 US US18/285,802 patent/US20250011773A1/en active Pending
- 2022-04-05 EP EP22718532.9A patent/EP4320236A1/en active Pending
- 2022-04-05 WO PCT/US2022/023559 patent/WO2022216759A1/en not_active Ceased
- 2022-04-05 MX MX2023011794A patent/MX2023011794A/es unknown
- 2022-04-05 IL IL307305A patent/IL307305A/en unknown
- 2022-04-05 CA CA3213590A patent/CA3213590A1/en active Pending
- 2022-04-05 KR KR1020237038205A patent/KR20240004467A/ko active Pending
- 2022-04-05 JP JP2023561290A patent/JP2024513237A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022216759A5 (https=) | ||
| JP7579589B2 (ja) | Ｒａｎタンパク質関連神経学的疾患を処置するための方法 | |
| EP3353298B1 (en) | Allele selective gene editing and uses thereof | |
| JP2024029136A (ja) | Ｄ因子を阻害するための組成物および方法 | |
| EP1191098B1 (en) | Pharmaceutical composition comprising dystrophin exon 45 for treatment of duchenne muscular dystrophy | |
| US5670634A (en) | Reversal of β/A4 amyloid peptide induced morphological changes in neuronal cells by antisense oligonucleotides | |
| EP1706426A2 (en) | Nogoa antibodies for the treatment of alzheimer disease | |
| TWI532842B (zh) | 針對凝乳酶之適體及其用途 | |
| JP2013525330A5 (https=) | ||
| JPH05500801A (ja) | アルツハイマーアミロイドポリペプチドを使用した薬学的組成物および処置方法 | |
| JP6599874B2 (ja) | Ｍｍｐ−９タンパク質の酵素活性を阻害するアプタマー | |
| US12083144B2 (en) | Dosage form for treating severe asthma | |
| JP2024545202A (ja) | Ｍａｐｔ ｒｎａ干渉剤 | |
| JP2025148338A (ja) | Ｒｎａ治療薬及びその使用方法 | |
| CA2342770A1 (en) | Ly6h gene | |
| JP2025516677A (ja) | Ｍａｐｔの発現を阻害するための組成物及び方法 | |
| JPWO2020205473A5 (https=) | ||
| EP4487119A2 (en) | Ran proteins in sporadic amyotrophic lateral sclerosis | |
| JPWO2019241648A5 (https=) | ||
| JP7750839B2 (ja) | ピロールイミダゾールポリアミド、ＴＧＦβ遺伝子発現抑制剤、医薬組成物 | |
| JP2005531624A (ja) | 脈管組織または血管の過形成に関連する疾患または障害の予防または治療方法 | |
| US20170298128A1 (en) | Methods and compositions for treating age-related disorders | |
| JP2025522559A (ja) | 慢性炎症性脱髄性多発神経炎などの神経系の疾患又は障害の治療における使用のためのアルファ１－アンチトリプシン | |
| US20250237666A9 (en) | Poly-ga proteins in alzheimer’s disease | |
| JP7264487B2 (ja) | キマーゼに対するアプタマー及びその使用 |